Takeaway

• Non-cancerous cells and their soluble factors play an important role in the resistance to immunotherapy.
• The composition and the activity of the tumour microenvironment (TME) may be targeted.

CD19 chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of the most severe and refractory cases of lymphoma,...